Boston Scientific, Farapulse Sign Deal for Treatment of AF

Boston Scientific Corporation BSX signed an investment agreement with an exclusive option to acquire Farapulse, Inc, a privately-held company developing a pulsed field ablation (“PFA”) system. The agreement has been signed to enhance the treatment of atrial fibrillation (“AF”) and other cardiac arrhythmias.

The Farapulse platform, which is an investigational device not available for sale, uses an ablation method based on pulsed electric fields (also known as irreversible electroporation) to regularize the electrical signals and prevent AF.

For investors’ note, Farapulse is pursuing regulatory approval in the United States and CE Mark approval in Europe. It has also received the FDA’s Breakthrough Designation for its endocardial ablation system in May 2019.

With the latest agreement, Boston Scientific aims to strengthen its position in the Electrophysiology business on a global scale. Notably, the Electrophysiology business is a component of the company’s broader Rhythm and Neuro arm.

Rationale Behind the Agreement

AF

Read More Read more